You  might be surprised at the very positive response the investor community can have towards a phI that fulfills its safety goals Bio. The majority of the seasoned biotech community really do know that that is a big, huge deal. Most people don't expect treatment effects until later trials - when the treatment dose is established. So - I don't think there will be the sell off you imagine. Also - there are many other measures of effect that will be drawn from this trial - the biomarkers being perhaps the most important - so that future trials can be designed around the most susceptible cancers - enhancing efficacy chances even more.